Abstract
We evaluated serum level of S100B in 11 patients with subcortical vascular dementia (SVD) and 19 patients with subcortical vascular mild cognitive impairment (SVMCI). Comparable groups were age-matched (79,18 ± 7,76 in SVD group, 77,84 ± 3,83 in SVMCI; Р = 0,53). 22 patients were as-sessed after 1 month therapy. It was shown that the serum S100B level significantly increased – (0,065 ± 0,020) μg/l (Р = 0,0005) in SVD patients comparing to SVMCI ones – (0,043 ± 0,010) μg/l. S100B level was significantly correlated with the clinical parameters: MMSE performance (rs = –0,61), CDR (rs = 0,58), attention task (rs = –0,46), pseudobulbar syndrome severity (rs = 0,37) and walking alteration (rs = 0,37). In patients with reduction of S100B level due to therapy (positive dynamics, n = 12) we registered significant improvement of some clinical parameters: MMSE, attention level, walking. In patients with increasing of S100B level (negative dynamics, n = 10) we didn’t registered improvement of any clinical parameters. We made the conclusion that the serum level of S100B could be used as marker of progression SVMCI into SVD and therapy effectiveness.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
